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CalciumDiastolic dysfunction is characterized by slow or incomplete relaxation of the ventricles during diastole, and
is an important contributor to heart failure pathophysiology. Clinical symptoms include fatigue, shortness of
breath, and pulmonary and peripheral edema, all contributing to decreased quality of life and poor prognosis.
There are currently no therapies available that directly target the heart pump defects in diastolic function.
Calcium mishandling is a hallmark of heart disease and has been the subject of a large body of research.
Efforts are ongoing in a number of gene therapy approaches to normalize the function of calcium handling proteins
such as sarcoplasmic reticulumcalciumATPase. An alternative approach to address calciummishandling in diastolic
dysfunction is to introduce calcium buffers to facilitate relaxation of the heart. Parvalbumin is a calcium binding
protein found in fast-twitch skeletal muscle and not normally expressed in the heart. Gene transfer of parvalbumin
into normal and diseased cardiac myocytes increases relaxation rate but also markedly decreases contraction
amplitude. Although parvalbumin binds calcium in a delayedmanner, it is not delayed enough to preserve full con-
tractility. Factors contributing to the temporal nature of calcium buffering by parvalbumin are discussed in relation
to remediation of diastolic dysfunction. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac
Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Heart failure is a clinical syndrome of heart pump insufﬁciency
and is a leading cause of death worldwide [1]. Heart failure is charac-
terized by poor prognosis and decreased quality of life, with primary
symptoms of breathlessness, fatigue, and edema of the lungs and
lower extremities [2]. Clinically, heart failure is divided into two
categories [3–5]: 1) heart failure with preserved ejection fraction
(HFpEF), and 2) heart failure with reduced ejection fraction (HFrEF).
Diastolic dysfunction, the decreased ability of the heart to relax in
diastole, is a key pathogenic feature of HFpEF, but can also be present
in HFrEF. Despite the high percentage of patients thought to have dia-
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rights reserved.systole has for decades been the main focus of therapeutic develop-
ment. Although mortality remains high, aggressive utilization of ACE
inhibitors, beta-blockers and diuretics has improved survival in
patients with reduced ejection fraction [6]. In comparison, these ther-
apies have largely proven ineffective at extending lifespan in heart
failure patients exhibiting primarily diastolic dysfunction (HFpEF) [3].
Normal heart pump function is driven by the intricately regulated
cyclic release and reuptake of calcium (Ca2+) to and from the cyto-
plasm of cardiac myocytes in the process of excitation–contraction
(E–C) coupling. During normal E–C coupling, depolarization of the
myocyte sarcolemma by an action potential induces a small inﬂux
of Ca2+ through the L-type Ca2+ channels (LTCC). This, in turn, trig-
gers a much larger release of Ca2+ from the sarcoplasmic reticulum
(SR) by stimulating the ryanodine receptor (RyR) Ca2+ release channel.
Ca2+ then interacts with sarcomeric troponin C and allows for actin–
myosin engagement and force production. Finally, Ca2+ is removed
from the cytoplasm, primarily via the SR Ca2+ ATPase (SERCA2a) and
the sarcolemmal sodium–calcium exchanger (NCX), leading to relaxa-
tion (Fig. 1). Defects in any of these mechanisms driving Ca2+ ﬂux
can lead to profound cardiac dysfunction.
In diastolic dysfunction, there may be an increase in sarcomere Ca2+
sensitivity and/or a decrease in the rate of Ca2+ reuptake via SERCA2a
and NCX, all leading to a state of Ca2+ overload. This leads to a slow or
incomplete relaxation of the ventricles, causing pulmonary edema and
hypertension. Chronically, increased diastolic Ca2+ also activates cell
death pathways and alters metabolic proﬁle. A number of reviews con-
tain detailed discussions of these topics [7–10].
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Fig. 1. Calcium cycling in the cardiac myocyte. Arrows represent Ca2+ ﬂux during one contractile cycle. A) Action potential allows Ca2+ entry through the LTCC, which B) triggers a
much larger Ca2+ release from the SR through the RyR. C) Ca2+ binds to myoﬁlament proteins, leading to force production. D) Ca2+ is then taken back up into the SR via SERCA2a,
or E) pumped out of the cell via NCX. S100A1 and PLN act as modulators of Ca2+ transport protein function. Parv buffers Ca2+ away from myoﬁlaments after force production.
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with preserved ejection fraction, there is considerable need for effec-
tive therapeutics directly targeting heart relaxation performance.
Most existing heart failure therapies act by reducing functional de-
mand on the myocardium rather than directly restoring myocyte
function. Although some diastolic dysfunction can be attributed to
systemic dysfunction, a principal defect of this disease is a
heart-intrinsic inability to effectively relax, where defects in Ca2+
handling play an important role. This review focuses on experimental
therapies speciﬁcally targeted at improving Ca2+ homeostasis in an
effort to improve relaxation performance in diastolic dysfunction.
The ﬁrst section presents an overview of how improving the
expression, function, and activity of several endogenous Ca2+ handling
proteins in the heart affects diastolic function in experimentalmodels of
heart failure. The second section presents an additional strategy for
normalizing Ca2+ handling through the introduction of a cytoplasmic
Ca2+ buffering system to enhance relaxation. Both sections emphasize
gene therapeutic strategies.
2. Endogenous calcium handling proteins
2.1. Phospholamban and SERCA2a
Reduced Ca2+ reuptake into the SR is a hallmark of the failing
heart and an important contributor to Ca2+ mishandling and slow
relaxation in diastolic dysfunction. Therefore, SERCA2a and its regulator
phospholamban (PLN) are attractive therapeutic targets, particularly as
SERCA2a activity can be decreased in failing hearts [11]. Earlier work
using adenoviral gene transfer of SERCA2a and PLN in isolated
cardiac myocytes demonstrated a role for SERCA2a to increase the
rate of Ca2+ transient decay and decrease diastolic Ca2+ levels, with
PLN counteracting this function [12,13]. Phosphorylation of PLN by pro-
tein kinase A (PKA) on serine-16 relieves its inhibition on SERCA2a,
allowing increased Ca2+ uptake into the SR (Fig. 1).Multiple approaches have been utilized to alter the function of
PLN and SERCA2a with the goal of improving Ca2+ handling and
thus diastolic function. The phospho-mimetic PLN(S16E) has been
utilized in several models to relieve PLN inhibition of SERCA2a includ-
ing the BIO14.6 dilated cardiomyopathic hamster model [14], a coro-
nary artery ligation model [15], and a rapid pacing model in sheep
[16]. Improvements in diastolic function including left ventricular
end diastolic pressure (LVEDP) and the load independent time con-
stant tau were found with PLN(S16E) treatment in these studies. An
alternative means to relieve SERCA2a inhibition is to inactivate PLN
or reduce PLN expression. The former was accomplished by
expressing an antibody against PLN, which increased relaxation rate,
measured by the negative pressure derivative (−dP/dt), in isolated
hearts from diabetic mice [17]. Reducing the amount of PLN protein
was achieved by injecting adeno-associated virus (AAV9) expressing
short hairpin RNA (shRNA) against PLN in aortic-banded rats, which
resulted in signiﬁcantly improved LVEDP and −dP/dt at one and
three months post injection [18]. However, another study showed
that a ﬁve-fold knockdown of PLN using AAV6 shRNA-PLN injected
into the left ventricle of dogs caused an increase in serum cTnI
3–6 weeks after treatment, and a decrease in fractional shortening
from 4 to 10 weeks after treatment. It was suggested that
shRNA-PLNmay interfere with endogenous microRNA pathways [19].
Recently, protein phosphatase 1 (PP1), which dephosphorylates
PLN and thus decreases SERCA2a activity (Fig. 1), was studied in
Muscle Lim Protein (MLP) knockout mice, a model of genetic dilated
cardiomyopathy. Mice were injected with AAV9 carrying PP1
shRNA, which resulted in a 25% decrease in PP1 protein expression.
Compared to controls, AAV9-shPP1 injected animals showed im-
proved diastolic function measured by tau and LVEDP, as well as im-
proved fractional shortening, LV dimensions, and LV posterior wall
thickness 12 weeks after gene transfer. Isolated cell studies provide
evidence that normalized Ca2+ handling was a major contributor to
the results seen [20].
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heart failure has been tested by expressing SERCA in various models
of heart failure. In aortic-banded rats, increasing Ca2+ reuptake into
the SR with adenoviral gene delivery of SERCA improved several
measures of systolic function and energy status, but did not normalize
banding-induced increases in heart weight. Relaxation performance
was not evaluated [21]. In another model, rat hearts with permanent
ligations of the coronary artery were injected with lentiviral vectors
harboring SERCA2a. Two months later, rat hearts receiving SERCA2a
had increased fractional shortening and improved left ventricular
volumes. In addition, in vivo hemodynamics showed increased ejec-
tion fraction and decreased tau six months after gene transfer of
SERCA2a. Six month survival after ligation was also increased in
animals with lentiviral SERCA2a [22].
SERCA2a activity is ATP-dependent and therefore its applicability
for treatment of the energy compromised failing heart has been ex-
plored. NMR spectroscopy was used to measure 31P in two studies.
SERCA2a AAV increased the phosphocreatine to ATP ratio (PCr:ATP)
in the hearts of aortic-banded mice [21]. A separate study reported
little change in energetics measurements between hearts of aortic
constricted mice with and without overexpression of SERCA2a [23].
Another study in rats undergoing aortic-banding showed SERCA2a
improved energy-efﬁciency of hearts measured by oxygen consump-
tion [24]. All of these studies used ex vivo hearts acutely perfused with
a glucose-containing buffer.
The strategy of SERCA2a delivery in heart failure has advanced to
clinical trials. AAV1-SERCA2a was injected via intracoronary infusion
into nine patients with heart failure in a Phase 1 clinical trial to assess
safety. To date, there have been no safety concerns reported [25].
AAV1-SERCA2a treatment was also investigated in a larger Phase 2
trial where the highest dose (1×1013 DNAse resistant particles) re-
duced the number of recurrent clinical events compared to placebo
after 12 months [26]. It will be important to continue monitoring
this cohort beyond the 12 month endpoint of this study to fully
address SERCA2a as a therapeutic treatment for the failing human
heart.
2.2. Na+/Ca2+ exchanger
The Na+/Ca2+ exchanger (NCX) is a sarcolemmal protein which
can function to transport Ca2+ into or out of the cell (Fig. 1). In heart
failure patients, mRNA and protein expression of NCX can be increased
[27], possibly a compensatory mechanism to decreased SERCA2a activ-
ity. Increased NCX expression has been correlated to increased diastolic
function in failing human heart explants [28] and therefore has been
studied experimentally as a way to improve heart function in healthy
and diseased models. In a rabbit model of heart failure, modest im-
provements in fractional shortening and maximum pressure derivative
(+dP/dt) were shown two weeks after administration of adenovirus
containing NCX (Ad-NCX), but diastolic parameters including −dP/dt
and LVEDP were not improved. Interestingly, isolated cells from these
Ad-NCX treated healthy and failing hearts had decreased contractility
compared to controls [29]. Myocyte relaxation measurements were
not reported in this rabbit model, however overexpressing NCX in a
mouse hypertrophy model rescued the hypertrophy-induced prolon-
gation of the Ca2+ transient in isolated myocytes [30]. In contrast to
NCX overexpression, NCX inhibition with NCX-shRNA protected isolat-
ed rat cardiac myocytes from calcium overload [31]. In the future, it
will be important to understand the cross-talk between SERCA2a and
NCX in the regulation of Ca2+ handling and the roles these proteins
play in different species and models of heart failure.
2.3. S100A1
The Ca2+ binding protein S100A1 has been shown to interact with
various Ca2+ handling proteins (such as RyR and SERCA) (Fig. 1) andaffect their activities [32]. S100A1 expression is decreased in heart failure.
Isolated human failing cardiac myocytes treated with Ad-S100A1
exhibited an increased rate of Ca2+ decay and decreased RyR Ca2+
leak, presumably by directly interacting with RyR. Ad-S100A1 treatment
also improved PCr:ATP in myocytes [33]. Cryoinfarcted hearts injected
with Ad-S100A1 showed a signiﬁcant improvement in contractility and
relaxation seven days after gene transfer. Cells isolated from these rat
hearts had an increased rate of cell relengthening and a decrease in
both diastolic Ca2+ and Ca2+ leak [34]. In another study, AAV6-S100A1
was injected 10 weeks after cryoinfarct. Cardiac function assessed eight
weeks later showed improved−dP/dt and LVEDP under basal conditions
and with isoproterenol. Additionally, mRNA expression of SERCA2a and
PLN was normalized [35]. In a large animal model of heart failure, pig
hearts were occluded for 2 h via balloon catheter, and two weeks later
AAV9-S100A1 was retrogradely injected into the coronary artery. Hearts
injected with AAV9-S100A1 showed signiﬁcantly improved whole heart
function, including diastolic parameters such as−dP/dt, LVEDP, and LV
enddiastolic diameter (LVEDD).Diastolic Ca2+and SRCa2+ leakwere in-
creased in isolated myocytes from occluded hearts, both of which were
corrected by S100A1. AAV9-S100A1 also improved the PCr:ATP and
NADH/NAD ratios, suggesting improved energetics [36].3. Ca2+ buffering
The introduction of a cytosolic Ca2+ buffering system offers an al-
ternative approach to normalize aberrant Ca2+ handling in diastolic
dysfunction. Conceptually, a Ca2+ buffer with maximal buffering ca-
pacity occurring during diastole could facilitate a faster removal of
Ca2+ from myoﬁlaments, thus improving the rate of relaxation in
the face of slow Ca2+ reuptake. A buffer could act as a temporary stor-
age depot for Ca2+ until it is taken up into the SR by SERCA2a or
transported out of the cell by NCX. In the case of a buffering system,
increased relaxation rate could occur without the need for increased
maximal energy production in an energy compromised failing heart.
Additionally, a novel buffer may act to correct multiple mechanisms
of Ca2+mishandling as opposed to targeting the activity of one protein.
These potential advantages provide incentive to explore Ca2+ buffers as
an additional or alternative approach to improving the expression or
activity of endogenous Ca2+-handling proteins as discussed in the pre-
vious sections.
Proteins containing EF-hand motifs are integral to the maintenance
of normal intracellular Ca2+ handling. EF-hands function as Ca2+
sensors and buffers, affecting multiple regulatory pathways and con-
trolling free cytosolic Ca2+ concentrations. They contain a 12-amino
acid cation binding loop ﬂanked by two α-helices in an approximately
perpendicular arrangement. EF-hands were so named because their
shape approximates that of a hand with the thumb and foreﬁnger
held approximately 90° apart as ﬁrst illustrated by Kretsigner and
Nockolds in 1973 [37].
Parvalbumin (Parv) is a ~12 kDa protein containing two functional
EF-hands. There are three distinct domains within Parv. The AB domain
(amino acids 1–40) at the N-terminus does not bind Ca2+. The CD
(amino acids 41–70) and EF (amino acids 80–108) domains each con-
tain an EF-hand that is capable of binding Ca2+ or magnesium
(Mg2+). Amino acids 1, 3, 5, 7, 9, and 12 of Parv's EF hand binding
loops interact with Ca2+ and Mg2+. Calcium is bound by the EF-hand
binding loops via seven coordinating oxygen atoms in a pentagonal
bipyrimidal geometry. Magnesium binding differs in that it features
only six coordination sites. The coordinating oxygen atoms come from
the side chains of amino acids 1, 3, 5, and 12, the backbone carbonyl
group of amino acid 7, and either a side chain oxygen atom from
amino acid 9 (CD loop) or a water molecule (EF loop). The 12th
amino acid side chain is unique in that it provides two coordinating ox-
ygen atoms for Ca2+ and one for Mg2+, allowing each to attain their
preferred coordination geometry [38].
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expressed in vivo. The α-Parv isoform is found in fast-twitch skeletal
muscle, GABAergic neurons, endocrine glands, brain, bone and kidney.
The β-Parv isoform (also referred to as oncomodulin in mammals) is
expressed in the thymus in chickens [39], and hair cells of the organ
of corti in mammals [40]. It has also been identiﬁed in human placental
tissue [41]. Parvalbumin is not expressed in detectable amounts in the
cardiac tissue of most species. In humans, theα and β isoforms contain
approximately 50% sequence homology [41].
The primary function of Parv is to buffer Ca2+. In fast-twitchmuscle,
Parv facilitates rapid relaxation by buffering Ca2+ away from myoﬁla-
ments after a contraction. An example of this buffering action is found
in the toadﬁshOpsanus tau, which has the highest known concentration
of Parv in its swimbladder muscle, 1.5–3.0 mM [42], enabling it to
contract and relax up to 200 times per second to produce its distinctive
“boatwhistle” mating call [43]. Parv Ca2+ and Mg2+ binding afﬁnities
vary between species and isoforms, but are generally in the range of
KCa2+=107–109 M−1 and KMg2+=103–105 M−1, respectively [44,45].
In a resting (non-contracted) cell, Mg2+ concentration (~1 mM) is
much higher than Ca2+ concentration (10–100 nM). As a result, the
EF-hands in Parv are primarily occupied by Mg2+ at baseline. When
the muscle cell contracts and Ca2+ concentration in the cell is high,
Ca2+ displaces Mg2+ in the EF-hand binding loops. The capability of
Parv to bind Mg2+ is imperative for the temporal nature of its Ca2+
buffering function. The time required for Mg2+ dissociation prevents
Ca2+ from binding to Parv immediately after Ca2+ release from the
SR, making it a delayed Ca2+ buffer [45].
Because of the important role for Ca2+ mishandling in heart failure
pathophysiology [46], the therapeutic potential of Parv has been tested
for increasing the relaxation rate of the heart in states of diastolic dys-
function. A working model for this concept is pictured in Fig. 2. When
cardiac myocytes are in the relaxed state in diastole, Mg2+ is bound
to the EF-hand loops of Parv. Upon depolarization at the start of systole,
excitation contraction coupling causes a rapid release of Ca2+ from the
SR, raising cytosolic Ca2+ to ~1 μM and leading to contraction of the
myoﬁlaments. The rise in Ca2+ concentration facilitates the removalSarcopl
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Fig. 2.Working model for Parv function in the heart. A) In the relaxed state, cytosolic Ca2+
the SR and binds to the myoﬁlament protein cTnC to facilitate contraction. Increased cytoso
itates rapid dissociation of Ca2+ from cTnC by buffering Ca2+ away from the myoﬁlaments,
and is replaced by Mg2+.of Mg2+ and the subsequent binding of Ca2+ to the EF-hands of Parv.
Because of the relatively slow off-rate of Mg2+ from Parv, Ca2+ is not
instantly buffered. This delay is vital for myoﬁlament cross-bridge
cycling to be able to occur. The “delayed” Ca2+ buffering effect would
ideally take place when Ca2+ is beginning to dissociate from myoﬁla-
ment proteins at the end of systole. The buffering capability of Parv pro-
vides temporary storage for Ca2+, enabling more rapid and complete
relaxation of themyoﬁlaments, even in the case of slow Ca2+ reuptake.
Thisworkingmodel has been tested extensively through a combina-
tion of primary cell culture and in vivo physiological studies. Earlier
work focused on understanding Parv-induced changes in cellular func-
tion by using adenoviral gene transfer of Parv in isolated adult rat cardi-
ac myocytes. Parvalbumin expression at levels approximating those
found in rat superior vastus lateralis muscle [47] signiﬁcantly enhanced
the rate of relaxation and Ca2+ transient decay in cells fromhealthy rats
and those with hypothyroidism [48] and hypertension-induced cardiac
hypertrophy [49]. In a dual gene transfer strategy, Parv rescued the
delayed relaxation phenotype displayed by both the A63V and E180G
mutations of α-tropomyosin [50]. Parv-transduced cardiac myocytes
from canineswith descending thoracic aortic coarctation, a large animal
model of diastolic dysfunction, demonstrated a marked improvement
in relaxation time [51].
In vivo studies have conﬁrmed ﬁndings from cellular studies. Direct
intramyocardial adenoviral gene delivery of Parv into the left ventricle
of rats with and without hypothyroidism decreased left ventricular
isovolumic relaxation time (LV IVRT) assessed by echocardiography.
LV IVRTwas inversely correlated to Parv protein expression. Additional-
ly, times to 50% and 90% relaxation and−dP/dt were improved during
measurement by in vivo hemodynamics micromanometry [52]. Aged
Fisher 344×BN F1 rats have evidence of diastolic dysfunction without
signiﬁcant ﬁbrosis. Adenoviral delivery of Parv in these rats resulted in
a signiﬁcant improvement in the load independent time constant tau
[53]. A similar study in aged Fisher 344 rats, which develop signiﬁcant
ﬁbrosis, also revealed improvement in diastolic dysfunction [54], pro-
viding evidence for the utility of Parv to improve diastolic dysfunction
with different etiologies.asmic
lum Ca
MgMg
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A
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is low and Mg2+ is bound to Parv. B) At the beginning of systole, Ca2+ is released from
lic Ca2+ concentration causes dissociation of Mg2+ from Parv. C) In diastole, Parv facil-
thus facilitating relaxation. D) As Ca2+ is returned to the SR, Ca2+ dissociates from Parv
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a decrease in contraction amplitude in both cellular and in vivo studies
has been observed with Parv. The Parv-induced increase in relaxation
rate is inversely related to contraction amplitude. This is thought to
occur when the maximal buffering capacity of Parv occurs prior to the
end of systole, resulting in sequestration of Ca2+ away from cTnC too
early in the contractile cycle. Several factors may be involved in this
process and are discussed in the following paragraphs.
First, changing the amount of Parv expression changes the maximal
buffering capacity. Increasing Parv concentrations in isolated cardiac
myocytes is achieved by increasing the number of days cells are cultured
after adenoviral gene transfer [47]. As demonstrated in isolated cell
experiments, and corroborated by mathematical modeling, Parv con-
centrations below 0.01 mM have minimal effects on cellular function,
and concentrations greater than 0.1 mM greatly increase relaxation
rate, but at the expense of contraction amplitude. Between 0.01 and
0.1 mM, Parv has modest beneﬁcial effects on relaxation without
adversely diminishing contraction amplitude in isolated cardiac
myocyte experiments [47,55], in which function is generally measured
by pacing cells at 0.2–1 Hz.
Heart rate is another factor affecting the buffering capacity of
parvalbumin. In a study of Parv transgenic mice [56], the dependence of
Parv function on pacing was demonstrated. Ex vivo analysis of whole
hearts from transgenic mice revealed modest increases in relaxation
rate and no effect on contraction amplitude at a pacing rate of 7 Hz.
However, as pacing was decreased to 2.5 Hz, transgenic hearts had a
more robust increase in relaxation rate, but the contraction amplitude
was severely diminished. Mathematical modeling gives insight into the
mechanism behind this effect. The rapid contraction-relaxation cycle
that occurs in hearts paced at 7 Hz does not allow enough time during
diastole for Ca2+ to completely dissociate from Parv and be transported
back into the SR before the beginning of the next contractile cycle. The
relatively slow off-rate of Ca2+ from Parv results in a percentage of
EF-hand binding sites being continuously occupied by Ca2+ under condi-
tions of fast pacing. This is similar to the results in skeletal muscle found
by Robertson et al. [57] where upon fast pacing the Parv binding sites
became saturated and lost buffering capacity.
Finally, intrinsic Ca2+ and Mg2+ afﬁnities of Parv affect physiologi-
cal function. This was demonstrated by comparing β-Parv from carp
with human α-Parv [49]. Carp β-Parv differs from human α-Parv by
having 16% increased Mg2+ afﬁnity and 218% increased Ca2+ afﬁnity
[49]. Comparing these two isoforms side by side, β-Parv was found to
decrease relaxation time and contraction amplitude to a greater extent
than α-Parv in isolated cells from Dahl salt-sensitive rats, a model of
hypertension-induced diastolic dysfunction. Extensive work has been
done with Parv isoforms to understand the role of various binding
loop amino acids to inﬂuence Ca2+ andMg2+ afﬁnities [58–61]. Knowl-
edge gleaned from this workmay be of importance in the identiﬁcation
of a calcium buffer with optimized kinetics for human heart physiology.
4. Conclusion
Diastolic dysfunction is a prominent feature in HFpEF, and can be
present in HFrEF as well. Although there are many precipitating causes
of diastolic dysfunction, Ca2+ mishandling is an important factor in its
development and progression. Because of the importance of Ca2+,
targeting Ca2+ handling proteins through gene therapeutic strategies
is a major area of study. This review has presented several different
and potentially complementary approaches to normalizing Ca2+ han-
dling in diastole. One approach is to target the expression, function or
activity of endogenous Ca2+ handling proteins in the heart. This offers
the opportunity to compensate for speciﬁc defects in Ca2+ reuptake in
diastole. The introduction of a cytosolic Ca2+ buffering system is anoth-
er approach to improve relaxation performance in diastole. Ca2+ buff-
ering does not target the expression or function of a speciﬁc Ca2+
handling protein, but rather provides a temporary storage depot forexcess Ca2+ regardless of the primary defect in Ca2+ handling. Buffer-
ing allows for efﬁcient removal of Ca2+ frommyoﬁlaments in diastole,
facilitating rapid relaxation, without increasingmaximal energy expen-
diture. The primary drawback of wild type Parv as a Ca2+ buffer
is its potential to reach maximal buffering capacity too early in the
contraction–relaxation cycle, thus inhibiting contraction amplitude.
Future work will explore the factors affecting the temporal nature of
Ca2+ binding by Parv to understand how to harness the therapeutic
potential of Ca2+ buffers for the improvement of relaxation, while not
compromising contractile function.References
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